MGMT and glioblastoma: Given that the lack of MGMT methylation is associated with higher temozolomide resistance in GBM patients [14], identifying this mutation early on in the disease course may help clinicians determine a more clinical beneficially treatment by weighing clinical efficacy versus known side effects of the drug.